Sanofi Sees Positive Results in Two Clinical Trials for Nieman-Pick Disease

Sanofi Sees Positive Results in Two Clinical Trials for Nieman-Pick Disease

Source: 
BioSpace
snippet: 

Paris-based Sanofi announced that its olipudase alfa had positive results in two different clinical trials for the treatment of acid sphingomyelinase deficiency (ASMD), also known as Nieman-Pick disease. Olipudase alfa is an investigational recombinant human acid sphingomyelinase.